Psilocybin shouldn't be categorized as a drug of abuse, but rather a therapeutic drug due to its numerous benefits. But its economic challenges, such as the difficulty in creating a for-profit model and the need for support and pre/post-therapy, remain a significant hurdle to making it widespread.